On October 26, 2023, ESSA Pharma Inc. (NASDAQ:EPIX) announced that updated data from the dose escalation portion of the Phase 1/2 trial of masofaniten (EPI-7386) and enzalutamide (Enz) was ...

VIENNA, Austria — The appropriate dose of pancreatic enzyme replacement therapy (PERT) for exocrine pancreatic insufficiency (EPI) depends on the root cause of the insufficiency, according to ...

As this is the first animal study on epinephrine-esmolol co-administration during myocardial ischemia and reperfusion injury, further studies in larger animals using multiple dosing protocols are ...

While millions of people carry little epinephrine pens to avert potentially ... majority of patients will get a clinically effective dose.” Gonzalez-Reyes and colleagues at Wilford Hall Medical ...